Skip to main content
. 2022 Aug 20;4(5):fcac215. doi: 10.1093/braincomms/fcac215

Table 1.

Participant characteristics with outcome characteristic of GSH conc., susceptibility, SMMSE score, SMMSE memory recall score, CDR score, CDR memory score, CDT score, TMT-A (sec) and TMT-B (sec) among HO, MCI and Alzheimer’s disease group

Characteristics HO (25) MCI (16) Alzheimer’s disease (31) P-value* Test statistics Effect size
Age (years) a 66.8 ± 5.30 68.06 ± 6.10 71.29 ± 7.70 0.039b F(2) = 3.41 0.090
Gender (M/F) 12/13 12/4 18/13 0.230c χ2 = 2.93 0.202
GSH conc. (mM) a 2.17 ± 0.39 (25) 1.81 ± 0.35 (13) 1.58 ± 0.37 (26) <0.001b F(2) = 15.65 0.339
Susceptibility (ppm) a 0.0064 ± 0.006 (22) 0.0061 ± 0.011 (16) 0.0140 ± 0.009 (22) 0.009 b,f F(2) = 5.43 0.154
SMMSE score a 29.40 ± 0.76 (25) 27.25 ± 6.15 (16) 16.66 ± 7.55 (29) <0.001d χ2 = 46.42 0.673
SMMSE Memory recall 2.56 ± 0.66 (25) 2.06 ± 0.68(16) 0.37 ± 0.68 (29) <0.001d χ2 = 47.15 0.683
CDR score (0/0.5/≥1) 22/0/0 1/13/1 1/4/23 <0.001c χ2 = 91.47 0.839
CDR Memory Score(0/0.5/≥1) 22/0/0 1/13/1 1/3/24 <0.001c χ2  = 95.59 0.858
CDT score a 1.12 ± 0.33 (25) 2.00 ± 1.59 (16) 4.67 ± 1.58 (24) <0.001d χ2 = 38.99 0.609
TMT-A (sec) a 47.76 ± 26.29 (25) 73.93 ± 51.14 (15) 133.47 ± 77.43 (15) 0.001e F(2) = 6.17 0.233
TMT-B (sec) a 106.52 ± 61.09 (25) 131.42 ± 75.38 (12) 318.50 ± 240.72 (8) 0.047d χ2 = 6.12 0.139
a

All continuous variables are represented as mean ± SD (N) and tested for normality using Shapiro–Wilk test and homoscedasticity using Levene’s test.

b

One-way ANOVA test was used for testing significant difference between groups.

c

χ2 test was used for testing significant difference between groups.

d

Kruskal–Wallis rank test was used for testing significant difference between groups.

e

Welch one-way ANOVA test was used for testing significant difference between groups.

f

Variables are transformed using the Box-cox transform for normality assumption.

*

All significant values were set at P < 0.05.